prikaz prve stranice dokumenta Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study
Pristup korisnicima matične ustanove
Znanstveni rad - Prethodno/kratko priopćenje
Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study
Journal of Neuroimmunology, 359 (2021); 577696. https://doi.org/10.1016/j.jneuroim.2021.577696
Habek, Mario; Jakob Brecl, Gregor; Bašić Kes, Vanja; Rogić, Dunja; Barun, Barbara; Gabelić, Tereza; Emeršič, Andreja; Horvat Ledinek, Alenka; Grbić, Nevena; Lapić, Ivana; Šegulja, Dragana; Đurić, Koraljka; Adamec, Ivan; Krbot Skorić, Magdalena

Citirajte ovaj rad

Habek, M., Jakob Brecl, G., Bašić Kes, V., Rogić, D., Barun, B., Gabelić, T. ... Krbot Skorić, M. (2021). Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study. Journal of Neuroimmunology, 359.. doi: 10.1016/j.jneuroim.2021.577696

Habek, Mario, et al. "Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study." Journal of Neuroimmunology, vol. 359, 2021. https://doi.org/10.1016/j.jneuroim.2021.577696

Habek, Mario, Gregor Jakob Brecl, Vanja Bašić Kes, Dunja Rogić, Barbara Barun, Tereza Gabelić, Andreja Emeršič, et al. "Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study." Journal of Neuroimmunology 359 (2021). https://doi.org/10.1016/j.jneuroim.2021.577696

Habek, M., et al. (2021) 'Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study', Journal of Neuroimmunology, 359. doi: 10.1016/j.jneuroim.2021.577696

Habek M, Jakob Brecl G, Bašić Kes V, Rogić D, Barun B, Gabelić T, i sur.. Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study. Journal of Neuroimmunology [Internet]. 10.2021. [pristupljeno 17.11.2024.];359. doi: 10.1016/j.jneuroim.2021.577696

M. Habek, et al., "Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study", Journal of Neuroimmunology, vol. 359, Listopad 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:960921. [Citirano: 17.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:960921
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study
AutorMario Habek
AutorGregor Jakob Brecl
AutorVanja Bašić Kes
AutorDunja Rogić
AutorBarbara Barun
AutorTereza Gabelić
AutorAndreja Emeršič
AutorAlenka Horvat Ledinek
AutorNevena Grbić
AutorIvana Lapić
AutorDragana Šegulja
AutorKoraljka Đurić
AutorIvan Adamec
AutorMagdalena Krbot Skorić
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
Sažetak (engleski)
Aim: To determine the influence of high-efficacy disease modifying therapy (DMT) on the development of IgG SARS-CoV-2 antibody response in COVID-19 convalescent people with multiple sclerosis (pwMS). Methods: Seventy-four pwMS taking high-efficacy DMTs (specifically natalizumab, fingolimod, alemtuzumab, ocrelizumab, cladribine and ublituximab) and diagnosed with COVID-19 and 44 healthy persons (HC) were enrolled. SARS-CoV2 antibodies were tested with Elecsys® Anti-SARSCoV-2 S assay. Results: pwMS taking high-efficacy DMTs had a significantly higher chance of having negative titer of SARS-CoV2 antibodies compared to healthy controls (33 negative pwMS [44.6%] compared to one negative HC [2.3%], p < 0.001). pwMS taking B-cell depleting therapy (ocrelizumab and ublituximab) had a significantly higher chance of having negative titer of SARS-CoV2 antibodies compared to pwMS on all other DMTs (29 negative pwMS on B-cell therapy [64.4%] compared to four negative pwMS on all other DMTs [13.8%], p < 0.001). Out of other DMTs, two (33.3%) pwMS taking fingolimod and two (16.7%) pwMS taking cladribine failed to develop IgG SARS-COV-2 antibodies. B-cell depleting therapy independently predicted negative titer of IgG SARS-CoV-2 antibody (Exp[B] =0.014, 95%CI 0.002–0.110, p < 0.001). Conclusions: A significant proportion of convalescent COVID-19 pwMS on high-efficacy DMTs will not develop IgG SARS-CoV-2 antibodies. B-cell depleting therapies independently predict negative and low titer of IgG SARS-CoV-2 antibody.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prethodno/kratko priopćenje
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Neuroimmunology
Brojčani podacivol. 359, 577696
p-ISSN0165-5728
DOIhttps://doi.org/10.1016/j.jneuroim.2021.577696
URN:NBNurn:nbn:hr:220:960921
Datum objave publikacije2021-10
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S016557282100223X
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-06-24 11:06:36